Raleigh, NC – According to filings with the U.S. Securities and Exchange Commission, Inceptor Bio is raising $60,811,621.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shailesh Maingi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inceptor Bio
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment. To achieve this goal, we assembled a purpose-driven team, recruiting pioneers in oncology, gene therapy, cell therapy and gene editing to join our mission. We provide a unique partnership model to university research programs focused on cutting-edge therapeutic approaches for oncology. The combination of our lab and manufacturing resources with the industry experience of our cell and gene therapy experts will advance therapeutics into the clinic with remarkable efficiency.

To learn more about Inceptor Bio, visit http://www.inceptor.bio/

Contact:
Shailesh Maingi, Chief Executive Officer
919-521-6400
https://www.linkedin.com/in/shaileshmaingi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved